In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Diagnostic Supply, A Powerhouse is Launched

Executive Summary

The merger of two leading diagnostic suppliers has created a national presence in the troubled diagnostic imaging distribution segment. Platinium Equities paid $250 million to buy the dx imaging distribution businesses of Philips Medical and PSS, but even at that cheap price, the road to success is fraught with obstacles. Notably, the imaging film segment is under considerable competitive pressure from the increasing popularity of PACS.

You may also be interested in...



PSS Redux--The Fall and Rise of a Physician Supply Company, Part II

After a meteoric rise through the late 1980s and early 1990s, PSS began to stumble badly, beginning with a difficult IPO in 1994 and culminating in a terminated acquisition offer in 2000. Having seen even its last hope--a face-saving merger--evaporate, PSS' senior managers had no choice but to try to turn the company around on their own. That's what they've done for the past eighteen months, with a strategy focusing on better financial controls, on the one hand, and a rededication to customer service, on the other.

At Least for Some, an Independence Day Celebration at Marconi

By acquiring Marconi Medical Systems in a $1.1 billion deal announced in July, Philips NV tacks on volume and adds scale to its medical systems business. Strategically, however, the move is part of a continuing response to competitor GE Medical Systems' ongoing acquisition efforts, which have challenged its competitors in medical capital equipment to get bigger to keep up.

Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel